| Authors: |
Gowda K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gupta M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aguilar A; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cruz C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Warner A; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rodriguez ER; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cuglievan B; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Milam J; Department of Epidemiology and Biostatistics, University of California-Irvine, Irvine, California, USA., Freyer DR; Department of Pediatrics, University of Southern California, Los Angeles, California, USA.; Department of Medicine, University of Southern California, Los Angeles, California, USA.; Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA., Miller KA; Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California, USA., Aune G; UTHealth Science Center San Antonio/Mays Cancer Center, San Antonio, Texas, USA., Eshelman-Kent D; UTHealth Science Center San Antonio/Mays Cancer Center, San Antonio, Texas, USA., Albritton K; Cook Children's Hospital, Fort Worth, Texas, USA., Koutroumpakis E; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Roth ME; Department of Epidemiology and Biostatistics, University of California-Irvine, Irvine, California, USA., Wang J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hildebrandt MAT; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
